Brought to you by 
Altus signs $25mm deal with Cystic Fibrosis Foundation; ends
26 Feb 2009
Executive Summary
The Cystic Fibrosis Foundation Therapeutics Inc.--the technology transfer arm of the Cystic Fibrosis Foundation--is paying Altus Biologics (protein-based therapeutics, diagnostics, and industrial products) up to $25mm in development milestones and providing the company with access to its clinical research network, so that Altus may conclude the development of its TheraCLEC-Total pancreatic insufficiency drug.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Altus signs $25mm deal with Cystic Fibrosis Foundation; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice